Loading…

Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis

Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic apheresis and dialysis 2013-08, Vol.17 (4), p.407-411
Main Authors: Knap, Bojan, Večerić-Haler, Željka, Benedik, Miha, Buturović-Ponikvar, Jadranka, Ponikvar, Rafael, Bren, Andrej F
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83
cites cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83
container_end_page 411
container_issue 4
container_start_page 407
container_title Therapeutic apheresis and dialysis
container_volume 17
creator Knap, Bojan
Večerić-Haler, Željka
Benedik, Miha
Buturović-Ponikvar, Jadranka
Ponikvar, Rafael
Bren, Andrej F
description Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.
doi_str_mv 10.1111/1744-9987.12087
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1420169411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1420169411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</originalsourceid><addsrcrecordid>eNqFkc1uEzEURi0EoqWwZoe8ZDOtfya2h10VkbRVKJEIAbGxPJ47YJjYxfaozUPwznVIG4kV3tjXOt9ZfBeh15Sc0nLOqKzrqmmUPKWMKPkEHR9-nh7esjlCL1L6SQhjNefP0RHjDadKkWP0Z-baGNrBpIznMdzmH3hmbA4RM46N7_AC-ozX4HN0dhxMxB9MSvjSd3CHnS-T8xm88RbwBWxC58ywTS7hpcmupNI7_CkXj4ldscQ0JrwI_ju-DjaP0Zvhn9RL9Kw3Q4JXD_cJ-jx7v5peVIuP88vp-aKytaSyalWvpCBCqZ40Xc2oILWQnRSCW2Z7YoUF09RUsJZOgDKrCAfTGwUT2ppO8RP0du-9ieH3CCnrjUsWhsF4CGPStGaEimKgBT3bozaGlCL0-ia6jYlbTYne7UDvWta7xvXfHZTEmwf52G6gO_CPpRdgsgdu3QDb__n06nz5KK72OZcy3B1yJv7SQnI50V-u5_rq63K6_rZq9JrfAw1FoZs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1420169411</pqid></control><display><type>article</type><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><source>Wiley</source><creator>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</creator><creatorcontrib>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</creatorcontrib><description>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</description><identifier>ISSN: 1744-9979</identifier><identifier>EISSN: 1744-9987</identifier><identifier>DOI: 10.1111/1744-9987.12087</identifier><identifier>PMID: 23931880</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Echocardiography ; Enzyme-Linked Immunosorbent Assay ; Female ; Fibroblast growth factor-23 ; Fibroblast Growth Factors - blood ; Heart Ventricles - pathology ; Hemodialysis ; Humans ; Hypertrophy, Left Ventricular - etiology ; Intact parathyroid hormone ; Kidney Failure, Chronic - therapy ; Left ventricular hypertrophy ; Male ; Middle Aged ; Nocturnal hemodialysis ; Parathyroid Hormone - blood ; Phosphorus - blood ; Prospective Studies ; Renal Dialysis - methods ; Time Factors</subject><ispartof>Therapeutic apheresis and dialysis, 2013-08, Vol.17 (4), p.407-411</ispartof><rights>2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis</rights><rights>2013 The Authors. Therapeutic Apheresis and Dialysis © 2013 International Society for Apheresis.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</citedby><cites>FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23931880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Knap, Bojan</creatorcontrib><creatorcontrib>Večerić-Haler, Željka</creatorcontrib><creatorcontrib>Benedik, Miha</creatorcontrib><creatorcontrib>Buturović-Ponikvar, Jadranka</creatorcontrib><creatorcontrib>Ponikvar, Rafael</creatorcontrib><creatorcontrib>Bren, Andrej F</creatorcontrib><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><title>Therapeutic apheresis and dialysis</title><addtitle>Ther Apher Dial</addtitle><description>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Echocardiography</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Fibroblast growth factor-23</subject><subject>Fibroblast Growth Factors - blood</subject><subject>Heart Ventricles - pathology</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Hypertrophy, Left Ventricular - etiology</subject><subject>Intact parathyroid hormone</subject><subject>Kidney Failure, Chronic - therapy</subject><subject>Left ventricular hypertrophy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nocturnal hemodialysis</subject><subject>Parathyroid Hormone - blood</subject><subject>Phosphorus - blood</subject><subject>Prospective Studies</subject><subject>Renal Dialysis - methods</subject><subject>Time Factors</subject><issn>1744-9979</issn><issn>1744-9987</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNqFkc1uEzEURi0EoqWwZoe8ZDOtfya2h10VkbRVKJEIAbGxPJ47YJjYxfaozUPwznVIG4kV3tjXOt9ZfBeh15Sc0nLOqKzrqmmUPKWMKPkEHR9-nh7esjlCL1L6SQhjNefP0RHjDadKkWP0Z-baGNrBpIznMdzmH3hmbA4RM46N7_AC-ozX4HN0dhxMxB9MSvjSd3CHnS-T8xm88RbwBWxC58ywTS7hpcmupNI7_CkXj4ldscQ0JrwI_ju-DjaP0Zvhn9RL9Kw3Q4JXD_cJ-jx7v5peVIuP88vp-aKytaSyalWvpCBCqZ40Xc2oILWQnRSCW2Z7YoUF09RUsJZOgDKrCAfTGwUT2ppO8RP0du-9ieH3CCnrjUsWhsF4CGPStGaEimKgBT3bozaGlCL0-ia6jYlbTYne7UDvWta7xvXfHZTEmwf52G6gO_CPpRdgsgdu3QDb__n06nz5KK72OZcy3B1yJv7SQnI50V-u5_rq63K6_rZq9JrfAw1FoZs</recordid><startdate>201308</startdate><enddate>201308</enddate><creator>Knap, Bojan</creator><creator>Večerić-Haler, Željka</creator><creator>Benedik, Miha</creator><creator>Buturović-Ponikvar, Jadranka</creator><creator>Ponikvar, Rafael</creator><creator>Bren, Andrej F</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201308</creationdate><title>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</title><author>Knap, Bojan ; Večerić-Haler, Željka ; Benedik, Miha ; Buturović-Ponikvar, Jadranka ; Ponikvar, Rafael ; Bren, Andrej F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Echocardiography</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Fibroblast growth factor-23</topic><topic>Fibroblast Growth Factors - blood</topic><topic>Heart Ventricles - pathology</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Hypertrophy, Left Ventricular - etiology</topic><topic>Intact parathyroid hormone</topic><topic>Kidney Failure, Chronic - therapy</topic><topic>Left ventricular hypertrophy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nocturnal hemodialysis</topic><topic>Parathyroid Hormone - blood</topic><topic>Phosphorus - blood</topic><topic>Prospective Studies</topic><topic>Renal Dialysis - methods</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Knap, Bojan</creatorcontrib><creatorcontrib>Večerić-Haler, Željka</creatorcontrib><creatorcontrib>Benedik, Miha</creatorcontrib><creatorcontrib>Buturović-Ponikvar, Jadranka</creatorcontrib><creatorcontrib>Ponikvar, Rafael</creatorcontrib><creatorcontrib>Bren, Andrej F</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Therapeutic apheresis and dialysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Knap, Bojan</au><au>Večerić-Haler, Željka</au><au>Benedik, Miha</au><au>Buturović-Ponikvar, Jadranka</au><au>Ponikvar, Rafael</au><au>Bren, Andrej F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis</atitle><jtitle>Therapeutic apheresis and dialysis</jtitle><addtitle>Ther Apher Dial</addtitle><date>2013-08</date><risdate>2013</risdate><volume>17</volume><issue>4</issue><spage>407</spage><epage>411</epage><pages>407-411</pages><issn>1744-9979</issn><eissn>1744-9987</eissn><abstract>Elevated levels of fibroblast growth factor 23 (FGF23) and phosphorus (P) have been linked to greater risks of left ventricular hypertrophy (LVH) in patients with end stage renal disease (ESRD). The aim of this study was to test if differences exist in a long nocturnal HD group in comparison with a group treated with standard daily thrice weekly dialysis. The attempt was to evaluate if elevated FGF‐23 levels, intact parathyroid hormone and P might be associated with left ventricular mass index (LVMI). Quantitative echocardiographic analyses were performed at baseline in 50 maintenance HD patients (17 women and 33 men, mean age: 56.4 ± 15.35 years, mean HD vintage: 9.06 ± 8.86 years, all patients are on HD thrice a week‐median duration 15 h/week, 10 of them on long nocturnal HD, median duration 24 h/week). LVMIs were calculated. FGF23 was measured in duplicate using a second generation C‐terminal enzyme‐linked immunosorbent assay and log of FGF‐23 values were computed. Mean LVMI was 136.44 ± 44.44 g/m2. Serum FGF‐23 levels were elevated when compared to population data with preserved kidney function (median 1388.5 RU/mL, range 252 to 24 336 RU/mL). There were no correlations recorded between log FGF‐23 levels and LVMI (r = 0.2, P = 0.66). LVMI was significantly lower in HD patients on long nocturnal dialysis procedure (r = −0.31, P = 0.05). Patients treated with long nocturnal HD showed lower LV mass, lower P‐values and higher 25‐OH‐D3 supply. Plasma FGF‐23 concentration was comparable between the groups and was not associated with LVMI in our maintenance HD patients.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>23931880</pmid><doi>10.1111/1744-9987.12087</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1744-9979
ispartof Therapeutic apheresis and dialysis, 2013-08, Vol.17 (4), p.407-411
issn 1744-9979
1744-9987
language eng
recordid cdi_proquest_miscellaneous_1420169411
source Wiley
subjects Adult
Aged
Echocardiography
Enzyme-Linked Immunosorbent Assay
Female
Fibroblast growth factor-23
Fibroblast Growth Factors - blood
Heart Ventricles - pathology
Hemodialysis
Humans
Hypertrophy, Left Ventricular - etiology
Intact parathyroid hormone
Kidney Failure, Chronic - therapy
Left ventricular hypertrophy
Male
Middle Aged
Nocturnal hemodialysis
Parathyroid Hormone - blood
Phosphorus - blood
Prospective Studies
Renal Dialysis - methods
Time Factors
title Fibroblast Growth Factor 23 and Left Ventricular Mass Index in Maintenance Hemodialysis Patients: Standard Versus Long Nocturnal Hemodialysis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T04%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fibroblast%20Growth%20Factor%2023%20and%20Left%20Ventricular%20Mass%20Index%20in%20Maintenance%20Hemodialysis%20Patients:%20Standard%20Versus%20Long%20Nocturnal%20Hemodialysis&rft.jtitle=Therapeutic%20apheresis%20and%20dialysis&rft.au=Knap,%20Bojan&rft.date=2013-08&rft.volume=17&rft.issue=4&rft.spage=407&rft.epage=411&rft.pages=407-411&rft.issn=1744-9979&rft.eissn=1744-9987&rft_id=info:doi/10.1111/1744-9987.12087&rft_dat=%3Cproquest_cross%3E1420169411%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4717-b8f8760688f09d42160467d7663c2cf0c6cea94162b15e12c803eafa8e51bad83%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1420169411&rft_id=info:pmid/23931880&rfr_iscdi=true